ReviewNanomedicine (London, England)2025
Emerging dendrimer-based RNA delivery strategies.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- From neuroinflammation to immune reprogramming: Nanozyme-Integrated nanoplatforms for neuroimmune modulation in Parkinson's disease.Materials today. Bio · 2026Article
- Camptothecin Nanoformulations: Recent Advances in Preparation, Bioactivities, and Clinical Perspectives.Annals of biomedical engineering · 2026Review
- Advancements in RNA-based therapies from bench to bedside.npj drug discovery · 2026Review
- Recent advances in metal-organic frameworks for therapeutic applications in periodontitis.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendrimers represent a class of polymers characterized by a highly branched architecture, precise composition, and a multitude of functional groups, garnering significant interest in biomedical applications. These are three-dimensional nanostructures characterized by a high degree of molecular homogeneity, adjustable size, multivalence, significant surface functionality, and high aqueous solubility.Dendrimers, owing to their significant properties, are currently utilized for drug delivery and are under investigation as potential carriers for nucleic acid-based vaccines. Nucleic acid, as a therapeutic molecule, offers several advantages, including safety, efficacy, and cost-effectiveness. These delivery systems may exhibit accelerated development timelines, reduced production costs, and enhanced storage and transportation efficiency. An essential aspect of DNA or RNA delivery technology is the selection of an efficient method of delivery.This review summarizes the classification, preparation, and formulation strategies for dendrimer delivery. Furthermore, the delivery of RNA via dendrimers for a range of disease conditions, including cancer, autoimmune disorders, infectious diseases, neurological disorders, and metabolic disorders, has been investigated and summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.